Why Animal Study Doses Don't Translate Directly to Humans

If you spend time in the peptide research literature, you'll quickly notice that dosing is almost always reported in per-kilogram units — micrograms per kilogram, nanograms per kilogram, and so on — applied to an animal subject, most often a rat or mouse. This is standard practice in pharmacology, but it creates a common point of confusion: a dose that sounds small (say, 10 µg/kg) is easy to misread as a ready-to-use human dosing instruction. It isn't.

Why body-weight scaling isn't the whole story

Naively scaling a rodent dose to a human by body weight alone ignores a well-documented pharmacological reality: smaller animals have a higher metabolic rate and faster drug clearance per kilogram of body weight than larger animals. The FDA's guidance on first-in-human dosing uses body-surface-area (BSA) normalization, not simple weight-based scaling, precisely because weight-based conversion tends to overestimate a safe human-equivalent dose. Converting correctly requires a species-specific conversion factor — and even then, the result is a starting point for toxicology assessment, not a validated therapeutic dose.

Route of administration matters as much as the number

On our BPC-157 profile, you'll notice the cited studies report meaningfully different effective doses depending on whether the compound was delivered intraperitoneally, intramuscularly, or orally in drinking water. That's typical: bioavailability, first-pass metabolism, and local tissue concentration all vary by route, so a dose figure is only meaningful alongside the route it was studied under.

Questions worth asking before trusting a dosing figure

1. What species and strain? Rat, mouse, and rabbit models don't scale identically.
2. What route was used? Intraperitoneal, intramuscular, subcutaneous, and oral doses are not interchangeable.
3. Single dose or repeated? A once-daily protocol over days or weeks produces different cumulative exposure than a single bolus.
4. How was the endpoint measured? Histological healing scores, biomechanical strength, and survival are different outcomes with different clinical relevance.
5. Has it been replicated outside the originating lab? A large share of the early peptide literature (BPC-157 included) comes from a small number of overlapping research groups.

The takeaway

Preclinical dosing data is genuinely useful — it's how a compound's biological activity gets characterized in the first place. But it answers the question "what did researchers give lab animals to produce this effect," not "what should a person take." Treat every dosing table on this site (and everywhere else) accordingly, and see our full disclaimer for more detail.